Shares of Eli Lilly (LLY -1.08%) jumped as much as 5.1% on Tuesday. However, as of 11:37 a.m. ET, the big pharma stock was down by 0.5%.The initial spike came after Lilly announced its 2023 fourth-quarter and full-year results. The company reported Q4 revenue of $9.35 billion, up 28% year over year. This result came in well above the average analysts' revenue estimate of $8.93 billion. Lilly posted Q4 earnings of $2.19 billion, or $2.42 per share, based on generally accepted accounting principles (GAAP). It ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

ToplineOut with electric vehicles, in with weight loss drugs: Investors have ditched one-time favorite Tesla for pharmaceutical giant Eli Lilly, as the early days of long-established Eli Lilly’s diabetes and weight loss drugs deliver explosive profits.Tesla's new Cybertruck at a Shanghai showroom.Future Publishing via Getty Images Key FactsTesla’s market value is down roughly $210 billion (27%) over the first five weeks of 2024 from $790 billion to about $580 billion, while Eli Lilly’s market capitalization ...

Eli Lilly (LLY) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.81%. A quarter ago, it was expected that this drugmaker would post a loss of $0.08 per share when it actually produced earnings of $0.10, delivering a surprise of 225%.Over the last four quarters, the company has surpas ...

Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its diabetes drug Mounjaro and newly-approved weight loss drug Zepbound.Eli Lilly reported global revenues of $9.35 billion during the last three months of 2023, an increase of nearly 30% from the same period the year before. This was buoyed by strong sales and higher prices of Mounjaro, the company’s blockbuster dia ...

About this content About Jeremy Cutler Jeremy has worked extensively in the world of financial journalism as a reporter at ICV News, deputy editor at S&P Marketscope and as a senior reporter for Thomson Financial’s Marketeye.  A qualified accountant, former finance director and with a degree in Economics, Jeremy is well placed to analyse and explain the ups and downs of UK, European and US stockmarkets in Proactive’s daily market report Read more About the publisher Proactive financial news and online br ...

Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker’s fourth-quarter earnings beat expectations, helped by a 16% jump in prices, and provided an upbeat 2024 revenue outlook. Net income rose to $2.19 billion, or $2.42 a share, from $1.94 billion, or $2.14 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $2.49 beat the FactSet consensus of $2.30. Revenue jumped 28.1% to $9.35 billi ...

Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included po ...

Key PointsEli Lilly stock is being bid up in the market just ahead of its earnings this week. As the sector sets up to attract more investment dollars, the stock could soar.Analysts at Wall Street's biggest names have lined up to boost the price targets for Eli, and markets have no issue with its 97% EPS growth projections today.5 stocks we like better than NVIDIANowadays, the market sends mixed signals to virtually every investor attempting to participate today, squeezing out a few percentage points of gai ...

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period. Analysts forecast revenues of $8.86 billion, representing an increase of 21.4% year over year.The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a ...